World Library  
Flag as Inappropriate
Email this Article

Factor XIII deficiency

Article Id: WHEBN0004304755
Reproduction Date:

Title: Factor XIII deficiency  
Author: World Heritage Encyclopedia
Language: English
Subject: List of MeSH codes (C15), Haemophilia, Khash, Iran, Nutritional anemia, Delta-thalassemia
Collection: Coagulopathies, Haemophilia
Publisher: World Heritage Encyclopedia

Factor XIII deficiency

Factor XIII deficiency
Classification and external resources
ICD-10 D68.2
ICD-9 286.3
OMIM 134570 134580
DiseasesDB 31412
eMedicine ped/3040
MeSH D005177

Factor XIII deficiency occurs exceedingly rarely, causing a severe bleeding tendency. The incidence is one in a million to one in five million people. Most are due to mutations in the A subunit gene (located on chromosome 6p25-p24). This mutation is inherited in an autosomal recessive fashion.

Deficiency of Factor XIII leads to defective cross-linking of fibrin and vulnerability to late re-bleeds when the primary hemostatic plug is overwhelmed. Bleeding tendencies similar to hemophiliacs develop, such as hemarthroses and deep tissue bleeding.

As Factor XIII is composed of two subunit protein, A and B, for which the genes are located on different chromosomes, administration of recombinant A subunit improves clot stability and is becoming a therapeutic option for patients with this condition.[1][2]


  • Therapy options 1
    • Fresh frozen plasma and cryoprecipitate 1.1
    • Factor XIII concentrates 1.2
    • Recombinant Factor XIII 1.3
  • See also 2
  • References 3

Therapy options

Fresh frozen plasma and cryoprecipitate

Fresh frozen plasma and cryoprecipitate are the mainstay of therapy for Factor XIII deficiency, but carry risk related to transfusion.

Factor XIII concentrates

Two commercially-produced factor XIII concentrates are currently available in Europe, one manufactured by Bio Products Laboratory (BPL) and only available in the United Kingdom. The other, Fibrogammin-P, is produced by Beringwerke of Germany. In the U.S. FXIII concentrate is only available under the Federal Drug Administration's Investigational New Drug (IND) Program, or through clinical trial.[3]

Recombinant Factor XIII

Recombinant Factor XIII (rFXIII) is the only prospective drug alternative to receiving blood transfusions, the traditional treatment for Factor XIII deficiency. Novo Nordisk’s rFXIII is not currently a marketed drug but finished phase III clinical trials in Spring 2010.[2] Although it is a recombinant protein, rFXIII subunit A is identical in structure and function to the A subunit of factor XIII naturally produced in the body by healthy individuals.[4] These patients need exogenous subunit A of factor XIII since they have a mutation which prevents production of the A subunit. However, since the B-subunit is located on a separate chromosome, factor XIII deficient patients actually produce the B-subunit normally. When these two subunits interact in the plasma, the enzyme is activated and can act within the clotting cascade.[1] rFXIII acts by inhibiting fibrinolysis factors which enzymatically cleave the fibrin matrix, leading to the ultimate formation of clots.

rFXIII is synthetically bio-engineered through a yeast expression system and administered intravenously. In clinical trials, the drug was administered once every four weeks or administered on-demand in order to treat bleeding episodes.[5] The introduction of rFXIII as a treatment for factor XIII deficiency eliminates the risk of pathogenic infection present in plasma-based treatments. rFXIII treatment would also not be dependent on blood donations, consequently increasing availability and product quality. One of the biggest fears in developing rFXIII was that the body would mount an immune-response to the protein; however, several safety and pharmokinetics studies have reported no immunogenic response to rFXIII or associated yeast products.[1]

See also


  1. ^ a b c Lovejoy A, Reynolds T, Visich J, Butine M, Young G, Belvedere M, Blain R, Pederson S, Ishak L, Nugent D (2006). "Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.". Blood 108 (1): 57–62.  
  2. ^ a b "Recombinant Factor XIII.". 2010. 
  3. ^
  4. ^ Muszbek, Laszlo et al. (1999). "Blood coagulation factor XIII: structure and function.". Thrombosis Research 94 94 (5): 271–305.  
  5. ^ Clinical Trials at Novo Nordisk. (2010). "Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients with FXIII Inherited Deficiency.". 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.